Abstract
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Keywords: Fanconi anemia, Clinical trials, Gene therapy, Bone marrow failure, Stem cells, Viral vectors.
Current Gene Therapy
Title:Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Volume: 16 Issue: 5
Author(s): Jennifer E. Adair, Julian Sevilla, Cristina Diaz de Heredia, Pamela S. Becker, Hans-Peter Kiem and Juan Bueren
Affiliation:
Keywords: Fanconi anemia, Clinical trials, Gene therapy, Bone marrow failure, Stem cells, Viral vectors.
Abstract: Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Export Options
About this article
Cite this article as:
Adair E. Jennifer, Sevilla Julian, Heredia Diaz de Cristina, Becker S. Pamela, Kiem Hans-Peter and Bueren Juan, Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170119113029
DOI https://dx.doi.org/10.2174/1566523217666170119113029 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Current Drug Discovery Technologies Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets The Role of Biomarker Genes in the Diagnosis and Treatment of Nonsmall Cell Lung Cancer
Current Respiratory Medicine Reviews Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
Current Cancer Drug Targets Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Epidermal Stem Cells - Role in Normal, Wounded and Pathological Psoriatic and Cancer Skin
Current Stem Cell Research & Therapy Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Curcumin, an Active Constiuent of the Ancient Medicinal Herb Curcuma longa L.: Some Uses and the Establishment and Biological Basis of Medical Efficacy
CNS & Neurological Disorders - Drug Targets Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry